Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease

ABSTRACT Introduction Haemophilia and von Willebrand disease (VWD) are inherited bleeding disorders requiring lifelong access to haemostatic therapies and coordinated multidisciplinary care. Lebanon's prolonged economic and healthcare crises have disrupted medication supply, financing, and access to specialized services, creating particular challenges for individuals with rare bleeding disorders. Aim To evaluate how Lebanon's prolonged economic and healthcare crises affected treatment access, care delivery, and health‐system support for patients with haemophilia and VWD. Methods We conducted a narrative review incorporating a retrospective descriptive analysis of aggregated data from the Lebanese Association for Haemophilia (LAH) beneficiary registry and programmatic records, complemented by World Federation of Hemophilia data and published literature. The principal longitudinal LAH dataset covered 2019–2023, with updated beneficiary‐registry data through 2026. Results The number of individuals recorded in the LAH beneficiary registry increased from 458 in 2019 to 547 in 2023 and reached 591 by June 2026. Reliance on humanitarian treatment support increased substantially during the crisis. Recorded donated‐product quantities rose from 873,262 units in 2019 to 4,002,211 in 2022, representing a 4.58‐fold increase (+358.3%), before declining to 2,459,558 in 2023. By 2026, LAH programmatic data indicated partial recovery in factor VIII and IX availability and expansion of non‐factor therapy, including emicizumab, although shortages persisted for selected VWD and rare bleeding‐disorder therapies. Conclusion Lebanon's overlapping crises substantially disrupted haemophilia and VWD care and increased reliance on LAH and humanitarian assistance. Although treatment availability has partially improved, important gaps remain. Sustainable progress will require reliable national financing and procurement, coordinated registry systems, and prospective clinical‐outcome monitoring.

Authors

Institutions

Publication Details

Journal
Haemophilia
Published
2026-11-14
DOI
https://doi.org/10.1111/hae.70451
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease

Ali Taher, Nicole Charbel, Khaled Baroudi, Adlette Inati et al.
Haemophilia
Hemophilia Treatment and Research
article

Impact of the Lebanese Crisis on the Treatment of Patients With Haemophilia and von Willebrand Disease

Ali Taher, Nicole Charbel, Khaled Baroudi, Adlette Inati, Peter Noun, Cesar Haddad, Sacha El Khoury, Hanady Samaha, Mohammad Hassan Hodroj, Solange Sakr
article en

Abstract

ABSTRACT Introduction Haemophilia and von Willebrand disease (VWD) are inherited bleeding disorders requiring lifelong access to haemostatic therapies and coordinated multidisciplinary care. Lebanon's prolonged economic and healthcare crises have disrupted medication supply, financing, and access to specialized services, creating particular challenges for individuals with rare bleeding disorders. Aim To evaluate how Lebanon's prolonged economic and healthcare crises affected treatment access, care delivery, and health‐system support for patients with haemophilia and VWD. Methods We conducted a narrative review incorporating a retrospective descriptive analysis of aggregated data from the Lebanese Association for Haemophilia (LAH) beneficiary registry and programmatic records, complemented by World Federation of Hemophilia data and published literature. The principal longitudinal LAH dataset covered 2019–2023, with updated beneficiary‐registry data through 2026. Results The number of individuals recorded in the LAH beneficiary registry increased from 458 in 2019 to 547 in 2023 and reached 591 by June 2026. Reliance on humanitarian treatment support increased substantially during the crisis. Recorded donated‐product quantities rose from 873,262 units in 2019 to 4,002,211 in 2022, representing a 4.58‐fold increase (+358.3%), before declining to 2,459,558 in 2023. By 2026, LAH programmatic data indicated partial recovery in factor VIII and IX availability and expansion of non‐factor therapy, including emicizumab, although shortages persisted for selected VWD and rare bleeding‐disorder therapies. Conclusion Lebanon's overlapping crises substantially disrupted haemophilia and VWD care and increased reliance on LAH and humanitarian assistance. Although treatment availability has partially improved, important gaps remain. Sustainable progress will require reliable national financing and procurement, coordinated registry systems, and prospective clinical‐outcome monitoring.

Haemophilia
University of Balamand (LB), Saint George Hospital (LB), American University of Beirut (LB)
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon